The University of North Carolina Brain Tumor Center, located in Chapel Hill, is hosting pre-clinical testing of a new nanoparticle technology called P80 DOXNP that has been developed by Vancouver, B.C.-based Advectus Life Sciences, Inc.

Ths study, which is being conducted to determine if the new technology is a legitimate method for delivering doxorubicin across the blood-brain barrier, will be randomized and placebo-controlled, accroding to a statement released by Advectus. Doxorubicin is chemotherapy that is used to treat some forms of cancer.

Last month Advectus entered into a contract with the University of Kentucky Research Foundation Center for Pharmaceutical Science and Technology to manufacture P80 DOXNP.